Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

Group 1 - The company, Baiyunshan, announced that its subsidiaries, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., participated in the national centralized procurement for the continuation of products whose agreements have expired [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which is based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual execution date of the selected results [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is about RMB 550 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it will further increase product sales, enhance market share, and positively impact the company's brand image and future business development [2]

Group 1 - The company, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., have participated in the national centralized procurement for the continuation of products from the first to eighth batches, with results published on February 10, 2026 [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which will last until December 31, 2028 [1] - The procurement volume will be based on the demand reported by medical institutions, with pricing determined by a tiered selection process [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798.19 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is around RMB 550.45 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it is expected to further increase product sales, enhance market share, and improve the company's brand image, positively impacting future business development [2]

Core Viewpoint - Sunshine Nuohua Pharmaceutical Research Co., Ltd. has received a first-instance judgment regarding a contract dispute over R&D expenses with Hunan Hengsheng Pharmaceutical Co., Ltd., which requires Hengsheng to pay 254,000 yuan in overdue R&D fees and corresponding penalties, while rejecting other claims from Sunshine Nuohua [1][2]. Group 1 - The court ruled that Hengsheng must pay Sunshine Nuohua 254,000 yuan within fifteen days from the judgment's effective date, along with a penalty calculated at a 5% annual interest rate from November 23, 2022, until actual payment [1]. - Sunshine Nuohua has fully provisioned for bad debts related to the overdue amount, indicating that the lawsuit will not negatively impact the company's current or future profits [2]. - The case is still within the appeal period, allowing Hengsheng to appeal to the Hunan Provincial High People's Court within fifteen days of receiving the judgment, introducing uncertainty regarding the final execution of the ruling [2].

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval for its generic drugs to pass the consistency evaluation of quality and efficacy, which is expected to enhance market competitiveness for the products [1][11]. Drug Information 1. Cefoperazone Sodium and Sulbactam Sodium Injection - The drug has been approved in three specifications: 1.0g, 1.5g, and 2.0g [1][6] - It is a third-generation cephalosporin antibiotic used for various infections, including respiratory, urinary, and intra-abdominal infections [6] - The product was originally developed by Pfizer and was first launched in Japan in June 1986, with its 1.0g specification approved in China in 1996 [6] - The sales revenue for Tianxin Pharmaceutical's cefoperazone sodium and sulbactam sodium injection in 2024 is projected to be RMB 15.897 million [7] - The company has invested approximately RMB 7.9186 million in the research and development of this product [7] 2. Clindamycin Phosphate Injection - The drug is available in two specifications: 2ml: 0.3g and 4ml: 0.6g, and was launched in 2006 [8][9] - It is primarily used for severe infections caused by sensitive anaerobic bacteria [9] - The sales revenue for Tianxin Pharmaceutical's clindamycin phosphate injection in 2024 is projected to be RMB 7.50787 million [10] - The company has invested approximately RMB 2.7329 million in the research and development of this product [10]

Trading Information Summary - On September 1, 2025, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332) closed at 26.61 yuan, up 0.23%, with a turnover rate of 1.73% and a trading volume of 243,300 shares, amounting to a transaction value of 651 million yuan [1] - On the same day, the net outflow of main funds was 27.59 million yuan, accounting for 4.24% of the total transaction value; the net outflow of retail funds was 25.91 million yuan, accounting for 3.98% of the total transaction value; while retail investors saw a net inflow of 53.50 million yuan, accounting for 8.22% of the total transaction value [1][3] Company Announcements Summary - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the consistency evaluation of generic drugs for two products: injectable cefoperazone sodium and sulbactam sodium (1.0g, 1.5g, 2.0g) and clindamycin phosphate injection (2ml: 0.3g, 4ml: 0.6g) [2] - The domestic sales revenue for injectable cefoperazone sodium and sulbactam sodium is projected to be 688.93 million yuan in 2024, with Tianxin Pharmaceutical's sales revenue for this product at 15.90 million yuan and R&D expenses around 7.92 million yuan [2] - The domestic sales revenue for clindamycin phosphate injection is expected to be 13.51 million yuan in 2024, with Tianxin Pharmaceutical's sales revenue for this product at 7.51 million yuan and R&D expenses approximately 2.73 million yuan [2]

Core Viewpoint - Baiyunshan (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplementary application of two injectable drugs, indicating a successful consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval - The injectable drugs approved include Cefoperazone Sodium and Sulbactam Sodium (1.0g, 1.5g, 2.0g) and Clindamycin Phosphate Injection (2ml: 0.3g, 4ml: 0.6g) [1] - Cefoperazone Sodium and Sulbactam Sodium is a third-generation cephalosporin antibiotic, effective against respiratory infections, urinary tract infections, and various intra-abdominal infections among others [1] - Clindamycin Phosphate Injection is primarily used for severe infections caused by sensitive anaerobic bacteria [1]

Core Viewpoint - Baiyunshan's subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for two injectable drugs, indicating a successful step in the company's pharmaceutical development and regulatory compliance [1] Group 1: Drug Approvals - The approved drugs include injectable Cefoperazone Sodium and Sulbactam Sodium (1.0g, 1.5g, 2.0g) and Clindamycin Phosphate Injection (2ml: 0.3g, 4ml: 0.6g) [1] - Cefoperazone Sodium and Sulbactam Sodium is a third-generation cephalosporin antibiotic, effective against respiratory infections caused by sensitive bacteria [1] - Clindamycin Phosphate Injection is primarily used for severe infections caused by sensitive anaerobic bacteria [1]

Core Viewpoint - Baiyunshan (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. ("Tianxin Pharmaceutical"), has received approval from the National Medical Products Administration for its supplementary drug application, indicating that its injectable formulations of Cefoperazone Sodium and Sulbactam Sodium (1.0g, 1.5g, 2.0g) and Clindamycin Phosphate Injection (2ml: 0.3g, 4ml: 0.6g) have passed the consistency evaluation for generic drug quality and efficacy [1] Group 1 - Tianxin Pharmaceutical's injectable formulations have successfully passed the consistency evaluation, which will enhance the market competitiveness of these products [1]

Core Viewpoint - Baiyunshan (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its supplementary drug application, enhancing the market competitiveness of its products [1] Group 1: Product Approval - Tianxin Pharmaceutical's injectable Cefoperazone Sodium and Sulbactam Sodium (1.0g, 1.5g, 2.0g) and Clindamycin Phosphate Injection (2ml: 0.3g, 4ml: 0.6g) have passed the consistency evaluation for generic drug quality and efficacy [1] - The approval is expected to improve the market competitiveness of the aforementioned products [1]